Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ra Capital Management, L.P. Sells 45,923 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $0.37, for a total value of $16,991.51. Following the transaction, the insider owned 378,666 shares in the company, valued at approximately $140,106.42. This represents a 10.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total value of $99,751.14.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Stock Up 8.0%

NASDAQ HOWL opened at $0.39 on Friday. Werewolf Therapeutics, Inc. has a 52 week low of $0.36 and a 52 week high of $2.38. The business’s fifty day simple moving average is $0.67 and its 200-day simple moving average is $0.72. The firm has a market cap of $19.16 million, a PE ratio of -0.32 and a beta of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. Research analysts expect that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

HOWL has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $3.75.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE grew its position in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Vanguard Group Inc. grew its position in Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares in the last quarter. Renaissance Technologies LLC grew its position in Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after acquiring an additional 221,766 shares in the last quarter. Jane Street Group LLC acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at about $409,000. Finally, Citadel Advisors LLC acquired a new position in Werewolf Therapeutics in the 3rd quarter valued at about $304,000. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.